Abliva — Share Issue/Capital Change 2020

Jul 31, 2020

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI), today announced an increase of the number of shares and votes in the company of 26,666,666 as a result of a performed directed rights issue, resolved by the Board of Directors on 22 April 2020 and completed on 15 June 2020.

Today, the last trading day of the month, there are in total 296,340,132 shares and votes in Abliva AB.

This information is information that Abliva AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2020-07-31 08:30 CEST.

For more information, please contact:

Catharina Johansson, CFO, IR & Communications +46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) info@abliva.com, www.abliva.com

For news subscription, please visit: http://abliva.com/press-releases/subscription-page/ Follow us on LinkedIn:https://www.linkedin.com/company/abliva Subscribe to our YouTube channel: https://www.youtube.com/channel /UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering Mitochondrial Health

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD+ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, is in preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Amended number of shares and votes in Abliva AB (publ)